| Developers: | Abbott Laboratories |
| Date of the premiere of the system: | February, 2020 |
| Branches: | Pharmaceutics, medicine, health care |
2020: Announcement
In the middle of February, 2020 Abbott provided the new implanted kardioverter-defibrillator (IKD) and a biventrikulyarny electropacemaker with function of the cardioversion defibrillation (IKD-SRT) Gallant.
IKD and IKD-RST Gallant devices are supplied with Bluetooth connection and a special application for the smartphone which allows to involve patients in process of treatment and to perform remote monitoring. Devices also differ in long service life of batteries and are compatible to MRT.
IKD are often recommended for prevention of sudden warm death at patients with defeat of peysmeykerny function and with risk of violations of a warm rhythm. Also are used by IKD-SRT for prevention of sudden death, but are in addition capable to recover a normal rhythm of reduction of ventricles in case of serious arrhythmia.
The Abbott Gallant system in combination with the myMerlinPulse application for smartphones allows to establish relation between doctors and patients and to obepechit constant control behind system operation. The application also allows doctors to watch far off patients and to reveal asymptomatic episodes of arrhythmias which can threaten their life.
 | The beneficial effect of remote monitoring repeatedly was confirmed in clinical trials. Such monitoring improves results of treatment of patients and reduces load of a health care system, - the vice president and the chief physician of division on monitoring devices of a warm rhythm Avi Fischer noted. - The new Abbott Gallant system gives to people an opportunity to see a doctor at any time, even being outdoors. |  |
Gallant IKD-SRT also includes the MultiPoint Pacing function developed by Abbott and SyncAV to help patients better to react to SRT.[1]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |